drugset / Trial / NCT01531647

A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers

NCT01531647

Phase 1 Completed 20 enrolled Hoffmann-La Roche
Non-randomizedCrossoverOpen-label

Summary

This open-label, multiple dose, single sequence crossover study will evaluate the drug-drug interaction between danoprevir/low-dose ritonavir and raltegravir in healthy volunteers. Subjects will receive raltegravir on Days 1-4 and, after a washout period of 3 days, danoprevir and low-dose ritonavir on Days 8-21, in combination with raltegravir on Days 18-21.

Timeline

Start
2012-01
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltegravir Other / unclassified 400 mg
Subject Ritonavir Other / unclassified 100 mg
Subject danoprevir Small molecule 100 mg

Indications

No indication recorded.